Elicio Therapeutics (ELTX) Convertible Debt (2024)
Elicio Therapeutics' (ELTX) quarterly Convertible Debt came in at $20.0 million in Q4 2024, up 1.0% on a QoQ basis from $19.8 million in Q3 2024.
Elicio Therapeutics (ELTX) Convertible Debt (2024) Analysis & Trends
Elicio Therapeutics (ELTX) has 1 years of Convertible Debt data on file, last reported at $20.0 million in Q4 2024.
- Quarterly Convertible Debt changed N/A year-over-year to $20.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $20.0 million (changed N/A YoY) and the FY2024 annual result came in at $20.0 million, changed N/A from the prior year.
- Convertible Debt grew to $20.0 million in Q4 2024, from $19.8 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $20.0 million in Q4 2024 to a low of $19.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20.03 Mn |
| Sep 30, 2024 | 19.84 Mn |